Cancer Research 2013-05-01

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

David End, Arturo Molina, Mary Todd, Michael L Meyers

Index: Cancer Res. 73(9) , 2926, (2013)

Full Text: HTML

Abstract

Structure	Name/CAS No.	Molecular Formula	Articles
	Spironolactone CAS:52-01-7	C₂₄H₃₂O₄S
	PTH-glycine CAS:2010-15-3	C₉H₈N₂OS

Evidence for aldosterone-dependent growth of renal cell carc...
2014-08-01
[Int. J. Exp. Pathol. 95(4) , 244-50, (2014)]

Mineralocorticoid receptor blockade improves coronary microv...
2015-01-01
[Diabetes 64(1) , 236-42, (2015)]

Patient with purulent pericarditis: a case doomed to fail?
2013-01-01
[Kardiol. Pol. 71(2) , 176-8, (2013)]

A chrysin analog exhibited strong inhibitory activities agai...
2011-09-01
[Am. J. Physiol. Regul. Integr. Comp. Physiol. 305(10) , R1133-40, (2013)]

Mineralocorticoid receptor agonists induce mouse aortic aneu...
2013-07-01
[Arterioscler. Thromb. Vasc. Biol. 33(7) , 1568-79, (2013)]

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Abstract

Related Compounds